| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f3b4c0b3b6bd1f85925ce86c04c43ca |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1694 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 |
| filingDate |
2020-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c088bef1b90d272e387ccbb35ccfc25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17ccf68cff8b1ac8f6073a1d08205c80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_635c316e4031b15fd094af5519243f67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acf3d69629c1dcb5829feaae22891a5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7f283b1b85bbdde82e6bb90337b3c4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cc8984168cbe0be9d2db7669f2a7816 |
| publicationDate |
2020-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020222421-A1 |
| titleOfInvention |
Modified release suspension of eslicarbazepine |
| abstract |
The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022147183-A1 |
| priorityDate |
2017-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |